VII. 5. Uncertainties and Ethical Statement

The evidence level for microbiota-based interventions is highly heterogeneous. According to the Cochrane and GRADE frameworks, fecal microbiota transplantation (FMT^[G]) has achieved **Level 1 evidence for recurrent Clostridioides difficile infection (rCDI)** — multiple randomized controlled trials (van Nood 2013, Cammarota 2015) and meta-analyses (Quraishi 2017) demonstrated consistent, clinically relevant effects ^[7]. This is, however, the only indication where the graft-based approach stands at this level.

All other uses — including metabolic syndrome, insulin resistance, mood and cognitive endpoints — currently rest on Level 4-5 evidence: mechanistic-associative data, small human studies, animal models, and observational cohorts. The 2012 Vrieze duodenal-FMT trial in insulin-resistant men showed transient improvement in peripheral insulin sensitivity, but the effect vanished by 6 weeks, and the 2017 Kootte replication study found only donor-specific, partial response. The UltraBiome program as a whole therefore cannot be said to be supported by randomized evidence — though its individual components (fiber, polyphenols, Mediterranean diet, sleep hygiene) are.

Surrogate vs. clinical endpoints. One of the most common biases in the microbiome literature is to present increased diversity (Shannon index, alpha diversity) as inherently beneficial. It is not: the 2018 Zmora Cell paper showed that probiotic assimilation is person-specific, and the clinical benefit of a “diversified” microbiota varies individually — indeed, after antibiotics, probiotics may delay natural recovery. Diversity is a biomarker, not an endpoint.

Publication bias and batch variability. Donor-specific engraftment rates in published FMT trials range from 15-92% (Smillie 2018, Podlesny 2022). This means that the same clinical protocol with the same capsule format and a different donor LOT can produce entirely different microbial outcomes. Studies reporting positive results are over-represented; “failed” donor studies often never reach publication.

> This book is the educational framework of the UltraBiome capsule program distributed by MicroBiome Bank. The authors apply the product clinically and have a commercial relationship with the distributor. This volume is not a neutral scientific review — there is commercial involvement. The reader must take this into account when weighing every claim.

According to the transparency guidelines of ISMPP (International Society for Medical Publication Professionals), commercial sponsorship must be disclosed prominently at the front of the document. Accordingly: this book is not a peer-reviewed clinical guideline, but structured patient education in the context of a specific product. For independent, conflict-free information, we direct the reader to the following resources:

• ECCMID / ESCMID FMT working group guidelines (Cammarota et al. 2017, 2021 update)
• ESPGHAN pediatric microbiota guidelines (for pediatric application)
• FDA Office of the Assistant Secretary for Health (OASH) — FMT IND status and Enforcement Discretion policy (2013, 2022, 2023)
• Cochrane Reviews — “Faecal microbiota transplantation” (living, updated document)

FDA (USA). The FDA classifies FMT as a drug; it is approved for recurrent Clostridioides difficile infection (BLA pathway: VOWST 2023, REBYOTA 2022). All other indications are off-label and IND-bound — including metabolic syndrome. In June 2019, the FDA issued a safety alert after a fatal case caused by an ESBL-producing E. coli (Massachusetts General Hospital), following which the minimum donor-screening requirements were substantially tightened.

EU MDR / IVDR and Hungarian regulation. In the EU, the classification of microbiota-based products is still evolving: the 2024 SoHO Regulation (Substances of Human Origin) placed human-derived microbiota grafts into a distinct category. In Hungary, OGYÉI (National Institute of Pharmacy and Nutrition) and ETT (Medical Research Council) approval is required for application within a clinical trial framework. The UltraBiome program described in this book is implemented under the treating physician’s responsibility as an individual application decision; it is not a registered medicinal product and does not replace any authorized treatment.

In IBS and depression-microbiome trials, the placebo response typically ranges from 30-50% (Ford 2020 meta-analysis on IBS; Cipriani 2018 antidepressant meta-analysis). The 90-day UltraBiome program can expect an even stronger placebo component, because:

• Lifestyle diary keeping is subjective monitoring — demand characteristics are significant: the patient “gives the response the program expects of them”.
• Hawthorne effect — observed behavior improves in itself (eating, sleep, movement), independently of the capsule’s effect.
• Regression to the mean — patients entering at their worst moment improve statistically even without intervention.

In metabolic syndrome, body weight, blood pressure, HbA1c, and lipid panel are objective endpoints — changes here are not placebo-explainable. But cravings, energy level, mood, “general well-being” are subjective, demand-sensitive, and the 90-day structure alone is enough for the patient to “feel better” — even with empty capsules.

Drug replacement vs. supplementation. The most serious ethical risk is that the patient attempts to replace metformin, SGLT2 inhibitor, or GLP-1 agonist with UltraBiome. This is not justified and not a supportable position — drug-dose modification is exclusively the treating physician’s authority, based on measured parameter improvement.

Weight stigma and body-weight focus. There is genuine tension between the HAES (Health At Every Size) perspective and metabolic optimization. The UltraBiome program does not promise and does not aim at weight loss — metabolic parameters (HbA1c, lipids, blood pressure) can improve independently. The book consciously avoids the “diet” and “weight-loss” framing.

The GLP-1 agonist era. Between 2024 and 2026, semaglutide and tirzepatide revolutionized the treatment of metabolic syndrome — with 15-22% sustained weight reduction. A real question: is UltraBiome in this context still relevant or technologically obsolete? Honest answer: the two do different things. GLP-1 agonists regulate appetite and insulin secretion; UltraBiome attempts to influence gut-microbiome-derived inflammatory and metabolite profiles — complementary, not competitive. But the patient’s choice is legitimate: publicly-financed GLP-1 through the Hungarian CDH (Central Drug Access) scheme is substantially cheaper than out-of-pocket UltraBiome.

Access inequalities. The program’s price is a selection gate that favors higher-SES groups — and at the same time, published clinical evidence comes from this same group. This is a feedback bias.

• Limitations of DTC microbiome tests. 16S rRNA sequencing only provides genus-level resolution; shotgun metagenomics is strain-level but more expensive, and clinical interpretation remains uncertain. “Send your stool and we’ll tell you what to eat”-type services have weak clinical validation (Tierney 2019).
• AI-based personalization. The continuing CGM-microbiome predictor model of the Segal lab (Weizmann Institute; Zeevi 2015 and successors) is promising: individualized glycemic response prediction is already working in research settings, with clinical adoption expected around 2027-2028.
• Live biotherapeutic products (LBP). The FDA approval of VOWST (oral capsule, Seres) and REBYOTA (Ferring) is a precedent: live microbiota grafts can reach market as regulated drugs. UltraBiome may in the future travel a similar pathway — currently it is not there.
• Patient-reported outcomes (PRO). The clinical trial standard is shifting from laboratory results toward patient experience (PROMIS, EQ-5D, IBS-QoL) — which may, in the long run, increase the importance of the 90-day diary-based monitoring.

This chapter is deliberately the last. Whoever has read this far knows not only the program but also its limits. The best health decisions are not born from blindly followed protocols, but from informed, two-sided collaboration — between the patient and the treating physician. This book is a tool, not a prescription; guidance, not promise; an option, not a guarantee.